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1. Introduction 
Clinical occurrence of acute myocardial infarction (AMI) has substantially increased over 
the last decade. More than 50% of the cases of coronary heart disease alone are covered 
under AMI. Thus, the prevalence of AMI poses a serious health care burden, demanding for
more strategic approaches. Exploration in molecular mechanisms underlying myocardial 
infarction (MI) has radically improved over the last half century. Novel pathways have not 
only provided in-depth knowledge of mechanistic approach to understand the 
pathophysiology of MI but also offer new strategies for its treatment. Currently, 
polypharmacy comprising ǃ-blockers, angiotensin converting enzyme (ACE) inhibitors,
angiotensin receptor blockers (ARB) and aspirin are generally adopted for treating patients
of MI. Surgical interventions include stenting procedures and percutaneous coronary 
interventions. Despite availability of these pharmacological and surgical therapies, they are 
associated with limitations encompassing side effects, recurrence, non-compliance and
interactions with other drugs. The early mortality rate from AMI is about 30%, with more
than half of these deaths occurring before the stricken individual reaches the hospital (AHA
report, 2003). Therefore looking towards the 21st century, now the question arises, can we
bring an ideal therapy for treatment of human MI where all the side effects, interaction and 
compliance issues can be eliminated? The answer might lie in an emerging area known as 
gene therapy. Cardiovascular gene therapy is one of those areas where administration of a 
particular gene would result in long term gene expression and preclude the heart from
various insults. In general an ideal gene therapy should have multifaceted approach such as 
1) It should be specific for the myocardial tissue 2) it should not cause potential adverse 
effects 3) it should not disrupt the vital genes 4) it should not increase the risk of other 
diseases such as predisposition to cancer and finally 5) it should be long enough to sustain 
and to prevent any recurrence of the disease. Most recent exciting development in gene
therapy includes formation of new blood vessels and improved blood flow to ischemic 
tissues induced by growth factors such as VEGF, HGF, FGF and PDGF. Furthermore,
improved calcium handing through SERCA2a, phospholamban, parvalbumin and S100A1
proteins offers a viable and attractive approach in the treatment of heart failure. In addition, 
modulation of ǃ-adrenergic receptor signaling through ǃ2 adrenergic receptor 
overexpression, GRK2/ǃARKct and Adenlyl cyclase 6 has yielded encouraging results in 
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268 Gene Therapy - Developments and Future Perspectives 
experimental models of MI. Thereafter, various cardiovascular diseases where gene therapy 
has made its mark in pre-clinical studies are angiogenesis for myocardial ischemia, re­
stenosis and bypass graft failure. Gene therapy with its specificity on myogenesis, cell cycle
activation anti-oxidant and anti-apoptotic pathways upregulates the cellular defense system 
and provides augmented cardioprotective response to injury and cardiac remodeling.
Success in animal models and in early phases of clinical trials of gene therapy in myocardial 
ischemic reperfusion setting further validates imminent use of gene therapy.
Mechanistically, gene therapy for MI must be aimed at activating key molecular pathways 
in myocardium that significantly alleviate the cardiac injury by inducing neo-angiogenesis,
strengthening anti-oxidant status of the myocardium, inhibiting necrosis/apoptotic 
pathways, inhibiting mitochondrial permeability transition pore and most importantly 
preserving the integrity of myocardium (remodeling). 
This chapter will basically focus on the significant results of gene therapy obtained in 
myocardial ischemia reperfusion injury in pre-clinical studies, phase I/II clinical trials and
their future implications to make gene therapy a completely bench to bed-side approach.
2. Preclinical aspect 
2.1 Role of angiogenesis in gene therapy
Perhaps, the most highly investigated and promising application of gene therapy which has
shown indispensable results in animal models of myocardial infarction is angiogenesis. 
Angiogenesis occurs as a result of multiple growth factors participating in the formation of
new blood vessels. Growth factors including vascular endothelial growth factor (VEGF),
hepatocyte growth factor (HGF), fibroblast growth factor (FGF) and platelet derived growth 
factor (PDGF), either alone or in combination, result in induction of angiogenesis. Therefore
gene therapy can act in very specific and targeted manner, i.e. either to activate the
pathways which up-regulate endogenous growth factors like hypoxia inducible factor-1
alpha (HIF-1ǂ), to inhibit endogenous anti-angiogenic processes or to induce growth factors
exogenously. The various angiogenic growth factors which have shown significant results in
animal models of myocardial infarction are as follows:
2.1.1 VEGF
Family comprises of five isoforms viz. VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental 
growth factor. The major function of VEGF is to regulate coronary vasculature development, 
blood vessel physiology, vasodilation, proliferation and migration of endothelial and
smooth muscle cells.
2.1.2 HGF
HGF shows its diversified action through coupling with c-Met receptor following tyrosine
kinase activation. HGF is a pleiotropic factor which promotes neo-vascularization, migration 
and proliferation of endothelial cells and inhibits apoptosis. In addition; morphogenesis, 
mitogenesis, motogenesis and neurite extension are the other effects shown by HGF.
2.1.3 FGF 
Family comprises of 22 distinct polypeptide growth factors and seven single-chain tyrosine 
receptor kinases. FGF is also known as heparin binding growth factor because of its higher 
affinity towards heparin and heparan sulfate. FGF displays its activities through auto­
phosphorylation via dimerization of its receptor. FGF actively participates in both the 
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269Preclinical and Clinical Prospects of Gene Therapy in Myocardial Infarction 
phases of angiogenesis/arteriogenesis i.e. early invasive phase and late maturative phase. 
Functionally, it is involved in migration and proliferation of endothelial and smooth muscle
cells, production of proteases and vessel maturation. 
2.1.4 PDGF
Family comprises of five isoforms viz. PDGF-A, PDGF-B, PDGF-C, PDGF-D and PDGF-AB
heterodimer; and acts through two distinct receptors namely ǂ and ǃ. Its function is to 
regulate cell growth and division. PDGF is a potent mitogen for smooth muscle cells of
mesenchymal origin. 
Growth 
Factors 
Species Outcome References 
VEGF-165
Rats, 
rabbits
Increased neovascularization and 
improved fractional shortening after MI 
Bull et al., 2003; 
Hao et al., 2007; 
Ruixing et al.,
2006. 
VEGF-165 Porcine
Increased myocardial blood flow, 
increased vasodilation with adenosine,
improved wall thickening and strain,
improved wall motion, increased 
ejection fraction and increased 
myocardial viability 
Choi et al., 2006; 
Ferrarini et al., 
2006; Jacquier et 
al., 2007; Tio et al., 
1999; Zhang et al., 
2002. 
VEGF-121
Rats, 
porcine 
Increased collateral circulation 
following MI 
Lee et al., 2000; 
Mack et al., 1998. 
VEGF­
B186 
Pigs,
rabbits 
improved myocardial perfusion and 
ejection fraction 
Lahteenvuo et al., 
2009 
VEGF-C Piglets 
augmented collateral formation and 
decreased wall thickening  after MI 
Patila et al., 2006 
VEGF-D Porcine 
improved perfusion when administered 
through a catheter mediated intra 
myocardial gene transfer method 
Rutanen et al.,
2004 
VEGF 
gene 
constructs 
Rat, 
mouse 
Reduced infarct size and induction of
angiogenesis 
Lee et al., 2003; Su 
et al., 2002; 
Yockman et al., 
2009 
HGF Rats, dogs Induction of angiogenesis
Aoki et al., 2000; 
Funatsu et al.,
2002; Wang et al., 
2006a 
HGF 
Mice, 
Swine, 
canine,
porcine 
Improved remodeling, decreased 
apoptosis, improved mobilization of 
stem cells for cardiac repair, decreased
fibrotic scar formation and improved 
contractility of the heart
Ahmet et al., 2002; 
Ahmet et al., 2003; 
Cho et al., 2008; 
Jayasankar et al., 
2003; Jin et al., 
2004; Li et al., 
2003; Taniyama et 
al., 2002; Yang et 
al., 2007; Yang et 
al., 2010
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270 Gene Therapy - Developments and Future Perspectives 
Growth 
Factors 
Species Outcome References 
HGF + 
ultrasound
mediated
micro
bubble 
destruction
Rat 
Increased angiogenesis, limitation of 
infarct size, and prevention of  LV
remodeling 
Kondo et al., 2004
FGF Pig 
Improved blood flow and MI by 
enhancing collateral formation 
Post et al., 2006
FGF-2 Pigs 
Improved LV functions and increased 
arteriogenesis 
Horvath et al., 
2002 
FGF-4 Pigs
increased perfusion and decreased LV 
dysfunction 
Gao et al., 2004
FGF-5 Pigs 
Improved blood flow, Reduced pacing-
induced  regional myocardial 
dysfunction 
Giordano et al.,
1996; Suzuki et al., 
2005 
PDGF-AB Rat 
Promoted angiogenesis and minimized 
the extent of myocardial infarction
Edelberg et al., 
2002 
PDGF + 
basic FGF 
Rat 
Promoted angiogenesis with more 
stable capillaries
Hao et al., 2004a 
PDGF-BB 
+ VEGF­
A165 
Rat 
Stimulated angiogenesis both at the 
capillary and arteriolar levels and 
transiently counteracted cardiac 
remodelling after MI
Hao et al., 2004b 
PDGF Rat Improved cardiac function Zheng et al., 2004 
PDGF Rats 
Improved post-infarction ventricular 
function without pulmonary toxicity 
Hsieh et al., 2006 
PDGF-BB 
+ FGF-2
Pigs
Enhanced myocardial collateral growth 
and significantly restored myocardial 
perfusion and function 
Lu et al., 2007
PDGF-BB Rats Significantly decreased MI
Krausgrill et al.,
2009 
Table 1. The examples of various growth factors in myocardial infarction.
2.2 Role of oxidative stress in gene therapy 
The human cells are replete with a number of molecules that function as antioxidants, i.e. 
which protect the cells from a group of molecules known as pro-oxidants. Anti-oxidants are
molecules that are capable of inhibiting the oxidation of other molecules. In this process,
they themselves get oxidized. On the other hand, pro-oxidants either generate free radicals 
or inhibit the anti-oxidant systems, thus predisposing the cell to oxidative damage.
Oxidative stress represents a condition characterized by an imbalance between the pro-
oxidant and anti-oxidant systems within the cell, leading to oxidative damage to the cell;
ultimately leading to lipid peroxidation, protein degradation and DNA damage and has 
been implicated in a vast variety of disorders; atherosclerosis, diabetes, myocardial 
infarction, myocardial ischemia-reperfusion injury, hypertension, heart failure,
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271Preclinical and Clinical Prospects of Gene Therapy in Myocardial Infarction 
cardiomyopathy and rheumatoid arthritis being just a few of them. Examples of ROS
include radicals like superoxide, hydroxyl, alkoxyl and peroxyl; and non-radicals like
hydrogen peroxide, hypochlorous acid and organic hydroperoxides. 
The observation that the level of antioxidants is increased during periods of oxidative stress 
has led to the finding that the synthesis of antioxidants is increased at the times of oxidative 
stress. This has led to the concept that administration of genes for antioxidants can combat 
the role of oxidative stress and thus protect cells and tissues from damage. Various studies 
and clinical trials have been carried out in this regard and the role of gene therapy for
antioxidants in myocardial ischemia prevention has been established in animal models. The
intramyocardial delivery of heme oxygenase-1(HO-1) into the left ventricle of rats using
AAVs (Adeno-Associated Virus) several weeks before myocardial infarction resulted in 
approximately 80% decrease in infarct size in association with decreases in oxidative stress, 
inflammation, and interstitial fibrosis and was accompanied by postinfarction recovery and
normalization of ventricular dimensions (Melo et al., 2002). Similar results were obtained
after transfer of gene for extracellular superoxide dismutase (EC-SOD); wherein 
recombinant adeno virus transfer into the myocardium of conscious rabbits of the gene 
encoding EC-SOD, three days before the induction of myocardial ischaemia by a 30-minute
coronary artery occlusion using a balloon occluder, afforded cardioprotection with a 
decrease in the region at risk and infarct size as compared to controls (Li et al., 2001). Its 
intracellular counterparts (Mn-SOD and Cu/Zn-SOD) have also been shown to decrease 
infarct size following ischaemia-reperfusion injury, as well as decrease apoptosis and delay 
induction of NF-κB (Michiels et al., 1994; Chen et al., 1998). Thioredoxins are potent
antioxidants that decrease p38MAPK signaling and superoxide anion generation and hence,
combat oxidative stress. Trx-1 gene therapy administered post-MI has been shown to 
promote angiogenesis, decrease apoptosis, reduce ventricular remodeling, and improve 
ejection fraction in diabetic rats (Samuel et al., 2010). Below are mentioned some important
anti-oxidants which have shown remarkable results in experimental models of myocardial
infarction.
2.2.1 HEME oxygenase-1 (HO-1) 
Heme oxygenase cleaves the heme ring at the alpha-methene bridge to form biliverdin, iron 
and carbon monoxide. Its activity is highest in the spleen, where old RBCs are sequestered 
and destroyed, leading to liberation of hemoglobin and its subsequent separation into heme
and globin. It has three isoforms: HO-1 (which is also referred to as heat-shock protein 32K
or HSP-32K) is inducible in response to oxidative stress, hypoxia, heavy metals, cytokines 
and a variety of other compounds. HO-1 has also been suggested to induce VEGF
formation. HO-2 is constitutive and is expressed under normal or homeostatic conditions. 
HO-3, unlike the other two isoforms, is not catalytically active, but has been postulated to
work in oxygen sensing. AAV delivery of HO-1 performed in MI-rat models demonstrated
an increase in cardiac remodeling and an improvement in cardiac function (Melo et al., 
2002). Studies performed in animals with human heme oxygenase-1 (hHO-1) administered 6
– 8 weeks prior to induction of ischaemia resulted in decreased mortality at 1 year, along 
with a decrease in infarct size, reduction in ventricular thinning, decreased inflammation
stress and interstitial fibrosis, decreased lipid peroxidation, and was accompanied by post-
infarction recovery and normalization of ventricular functions (Melo et al., 2002). 
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272 Gene Therapy - Developments and Future Perspectives 
2.2.2 Superoxide dismutase (SOD) 
The enzyme superoxide dismutase (EC: 1.15.1.1) was first discovered by Fridowich and 
McCord (McCord & Fridovich, 1988). It scavenges the superoxide (O-2.) radical and causes
its dismutation into water and hydrogen peroxide by the following reaction –
2O-2. + 2H →H2O2 + O2 
The enzyme has three isoforms – 1. Cytosolic (Cu/Zn-SOD) or SOD-1, dependent on copper 
and zinc (Cao, et al., 2008). 2. Mitochondrial (Mn-SOD) or SOD-2, dependent on manganese
(Borgstahl, et al., 1996) and 3. Extracellular (EC-SOD) or SOD-3. The genes for these are 
located on chromosomes 21q22.1, 6q25.3 and 4p15.3 respectively. Cu/Zn-SOD is dimeric 
and the other two are tetrameric in structure. All of them have improved left ventricular 
function and increased survival in rat ischaemia-reperfusion models (Michiels et al., 1994, 
Chen et al., 1998; Li, et al., 2001). Studies on EC-SOD in rat ischaemia-reperfusion models 
have demonstrated decreased myocardial stunning and infarct size (Li et al., 2001). Mn-SOD
and eNOS administered together have also led to decreased infarct size in animal ischaemia­
reperfusion models (Abunasra et al., 2001). 
2.2.3 Thioredoxins 
Thioredoxins are another group of antioxidant proteins that are ubiquitously found in many
organisms and are encoded by the TNX gene in humans (Wollman et al., 1988). They have a
12 kDa tertiary structure, that contains a dithiol-disulfide active site and facilitate the
reduction of other proteins by a cysteine thiol-disulfide exchange. The amino acid sequence 
of thioredoxins is characterized by two vicinal cysteines in a CXXC motif which provide the
enzyme the ability to reduce various substrates, such as ribonucleases, chorionic 
gonadotrophins, coagulation factors, glucocorticoid receptors and insulin. The thioredoxins
also act as electron donors to peroxidases and ribonucleotide reductase (Arner & Holmgren,
2000). 
The summary of the researches carried out on antioxidant gene therapy in MI is 
summarized in the table 2.
Gene Model Outcome References 
HO-1 Rat I/R
Decrease in infarct size. Decrease in
oxidative stress, inflammation and 
interstitial fibrosis. Post-infarction 
recovery with normalization of 
ventricular dimensions 
Melo et al., 2002 
SOD Rat I/R
Decreased stunning. Decreased infarct
size following I/R injury. Improved left 
ventricular function. Increased survival
Michiels et al.,
1994 & Chen et al., 
1998, Li et al., 2001 
TRX-1 
Post-MI 
diabetic 
rats 
Angiogenesis. Decreased apoptosis. 
Decreased ventricular remodeling.
Improved ejection fraction. 
Samuel et al., 2010 
SPHK1 Rats 
Improved systolic and diastolic 
functions of the heart and improved 
peak contraction velocity
Jin et al., 2007
Table 2. Examples of various anti-oxidants studied for gene therapy.
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273Preclinical and Clinical Prospects of Gene Therapy in Myocardial Infarction 
Gene Species Outcome Reference 
Bcl-2 Rabbits
Reduced apoptosis, reduced ventricular 
dilatation and decreased wall thinning
Chatterjee et al., 
2002 
Apoptosis 
repressor 
gene 
Rabbits 
Inhibition of apoptosis, decreased LV 
dilatation with preserved ejection fraction
Chatterjee et al., 
2003 
Cardio­
trophin-1 
(CT-1) 
Mouse 
Decreased apoptosis, decreased infarct
size, decreased caspase-3 activation and
improved ventricular pressure indices
Ruixing et al., 2007 
Akt Rats
Limitation of infarct size, improved 
myocardial contractility and reduced 
infarct size
Cittadini et al., 2006; 
Miao et al., 2000
sTNFR1 
(TNF-ǂ
antagonist) 
Mice
Reduced infract size and improved cardiac 
function
Sugano et al., 2004
HSP 20 Rats 
Improved LV end systolic and end 
diastolic pressures, reduced apoptosis and 
decreased infarct size
Zhu et al., 2005
HSP 70 Rabbits Decreased infarct size Okubo et al., 2001
HSP 72 Rats 
Decreased apoptosis and 
prevented MI
Suzuki et al., 2002 
Kallikrein 
gene Rats
Decreased apoptosis, endothelial
dysfunction and preservation of cardiac
output
Agata et al., 2002
Sonic 
hedgehog 
homolog 
(Shh) 
Mice, Rats 
Preserved ventricular function by 
enhancing neovascularization, reduced 
apoptosis and fibrosis
Kusano et al., 2005
Troponin I 
type 3 
interacting
kinase
Mice
Decreased MI and inhibition of 
remodeling 
Lai et al., 2008
Leukemia 
inhibitory 
factor (LIF) 
Rats Preservation of rat myocardium post-MI Berry et al., 2004
Cluster of 
Differentiati 
on 151 
(CD151) 
Pigs and
rats 
Promoted neovascularization and 
improved cardiac function
Wang et al., 2006b, 
Zuo et al., 2009
p38 kinase +
active MAP 
kinase
kinase 3b
Rats 
Reduced infarct size, decreased apoptosis,
increased capillary density, decreased
fibrosis and improved ejection fraction
Tenhunen et al.,
2006
Table 3. The examples of various proteins involved in apoptosis studied for gene therapy.
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274 Gene Therapy - Developments and Future Perspectives 
2.3 Role of apoptosis in gene therapy 
Apoptosis means programmed cell death. It is a physiological phenomenon that normally 
occurs during the embryonic development in humans and also serves as a protective 
response in case of irreparable DNA damage to avoid the multiplication of defective cells. 
Two various pathways are involved in induction of apoptosis. The extracellular pathway 
involves stimulation of death receptors that transduce signals to the nucleus to activate 
caspases. The intracellular pathway involves increase in the permeability of the inner 
mitochondrial membrane that causes leakage of pro-apoptotic molecules like cytochrome c 
into the cytoplasm that directly activate the caspases. The end-result is the activation of 
caspases that digest the protein cytoskeleton of the cell. The distinct family of Bcl proteins is 
involved in apoptosis, with Bcl-2 and Bcl-x acting as anti-apoptotic factors; while Bax and 
Bak act as pro-apoptotic factors. 
The pathways of apoptosis provide an excellent target for gene therapy as inhibition of 
apoptosis allows the cells to survive. Gene therapies with pro-apoptotic molecules and 
genes that transcribe proteins that suppress the anti-apoptotic proteins have been tried in
animal models with sufficiently encouraging results, which are yet to be supplemented by 
results from clinical trials (Table 3). 
2.4 Role of calcium signaling in gene therapy 
The handling of Ca2+ during excitation–contraction (EC) coupling is an important feature of 
the cardiomyocyte contraction. In cardiomyocytes, EC coupling begins with the initiation of 
action potential, whereby, Ca2+ enters the cell through voltage-gated L-type Ca2+channels
and triggers the ryanodine receptor (RyR) to extrude Ca2+ from the sarcoplasmic reticulum 
(SR) into the cytosol. This Ca2+induced Ca2+ release trigger is a crucial step in cardiomyocyte
contraction through Ca2+ binding to troponin C within the myofilaments of the sarcomere. 
Furthermore, it is again imperative to remove the Ca2+ from the cytosol to initiate the
relaxation of sarcomere which is mainly dependent on sarco/endoplasmic reticulum Ca2+-
ATPase 2a (SERCA2a) and sarcolemmal Na+–Ca2+exchanger (NCX). Moreover, distortion of 
Ca2+ handling in cardiomyocytes occurs due to decreased SR Ca2+ store and a prolonged
Ca2+ transient, which is generally a consequence of increased NCX, reduction in SERCA2a, 
decreased phospholamban (PLN)/SERCA2a ratio and increased open probability of the
RyR. In addition, these abnormalities in Ca2+ handling cause dysfunctional contractile
performance and may increase the risk of cardiac arrhythmias and cardiac remodeling.
Because myocardial contractility is dependent on ventricular Ca2+ handling, therefore, 
genetic modification of molecules involved in dysfunctional cardiomyocyte Ca2+ handling 
could be a viable and attractive target in the treatment of heart failure. The major proteins 
which participate in handling of calcium during cardiomyocyte contraction are discussed 
briefly: 
2.4.1 Sarco/endoplasmic reticulum Ca2+-ATPase (SR Ca2+-ATPase, SERCA)
SERCA, a calcium ATPase (type P-ATPase) exists in the SR within muscle cells and transfers
Ca2+ from the cytosol of the cell to the SR at the cost of ATP hydrolysis during muscle 
relaxation. There are three isoforms of SERCA viz. SERCA1-3, which have been shown to
play distinct roles in various cells. Of the three isoforms available SERCA2 plays a 
significant role in calcium handling during myocyte contraction. Of note, SERCA2a activity 
is reduced in heart failure, resulting in decreased calcium uptake and impaired relaxation.
Furthermore, SERCA2a activity in myocytes is controlled by phospholamban (PLN), a small 
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275Preclinical and Clinical Prospects of Gene Therapy in Myocardial Infarction 
inhibitory peptide that inhibits SERCA2a in its dephosphorylated form; whereas
phosphorylated PLN reduces this inhibition. Therefore, SERCA2a gene therapy would aim 
to increase SERCA2a activity, which in turn would increase calcium uptake and thus
improve diastolic relaxation. In addition it would also increase contractile reserve because of 
higher SR calcium concentration.
2.4.2 Phospholamban (PLN) 
PLN is a protein which is encoded by the PLN gene in humans. The important function of
PLN is to regulate Ca2+ pump in skeletal and cardiac muscle cells. It has been observed that 
dephosphorylated phospholamban (PLB) inhibits SERCA2a activity, while proteins such as 
calcium-calmodulin-dependent protein kinase (CAMkinase) and protein kinase A (PKA) 
cause phosphorylation of PLB to relieve this inhibition. This cross-talk between PLB and
SERCA2a controls the calcium content of the SR and normal myocardial contractility. The 
role of PLB in cardiac Ca2+ handling has been elucidated through PLB-knockout mice; that
displayed enhanced Ca2+ kinetics and showed significantly increased cardiac contractility. 
Paradoxically, PLB overexpressing mice showed impaired Ca2+ cycling associated with 
depressed contractile parameters. Thus, PLB plays a nodal role in the regulation of SR Ca2+ 
homeostasis through its potent action on SERCA2a activity which in turn leads to slower 
cytosolic Ca2+ decay and prolonged diastolic relaxation.
2.4.3 Parvalbumin
Parvalbumin is a calcium-binding albumin protein that resides in fast-contracting muscles
(highest levels), in the brain and some endocrine tissues. Gene therapy with parvalbumin, a
Ca2+ sequestering protein, potentially provides an energy-independent removal of cystosolic
calcium and thus improves the functioning of the heart. Adenovirus (AdV) parvalbumin 
delivery in hypothyroid rat hearts led to an increased rate of calcium removal and an 
improved rate of diastolic relaxation. Thus, parvalbumin may constitute a potentially 
attractive mode of correcting the prolonged diastolic Ca2+ decay generally seen in heart 
failure without further energy deprivation. Likewise, AdV-parvalbumin delivery to isolated
cardiomyocytes from dog hearts after thoracic aortic coarctation resulted in improved
relaxation kinetics but depressed sarcomere shortening at higher parvalbumin 
concentrations. This was probably due to inadvertant calcium removal during systole. 
Although potentially promising target for gene therapy in heart failure, further studies 
addressing the impact of long-term parvalbumin expression in relevant models of HF is
warranted to clarify its role.
2.4.4 S100A1
S100A1 belongs to the S100 protein family (the largest Ca2+ binding protein subfamily) and
appears to play multiple and inimitable roles in cardiomyocyte Ca2+ handling. It is highly 
expressed in the heart and localized to SR, sarcomere and the mitochondria. It is 
demonstrated by some researchers that myocardial levels of S100A1 are decreased in heart
failure. So, S100A1 gene delivery to cardiomyocytes may result in an increased isometric
contraction followed by an increase in the amount of Ca2+ pumped into the SR. Adrenergic
receptor stimulation in the presence of S100A1 overexpression enhanced maximal
contractile performance. Furthermore, S100A1 decreases the Ca2+ concentration during
diastole and augments Ca2+ release during systole by regulating both RyR and SERCA2a. In
addition, S100A1 also augments SERCA2a activity during the relaxation phase and 
improves diastolic relaxation.
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276 Gene Therapy - Developments and Future Perspectives 
Target 
Gene 
Species Outcome References 
SR CA2+ 
ATPASE  
Isolated 
cardio 
myocytes
Rats 
SERCA2a 
In vitro restored the contractile function of 
cardiomyocytes isolated from failing human
hearts.
Improved systolic and diastolic function 
along with improved survival (63% versus
9%).
Improved left ventricular systolic pressure, 
enhanced ventricular pressure rise decline 
(dp/dt), normalized rate of isovolumic 
relaxation. 
Adenoviral gene transfer of SERCA2a in a 
rat model of heart failure (aortic banding)
improved left ventricular function. 
del Monte et al., 1999
del Monte et al., 
2001a
del Monte et al., 
2001b
Miyamoto et al., 
2000
Mice Impaired Ca2+ cycling associated with
depressed contractile parameters . 
Kadambi et al., 1996
Human Improvement in contraction and relaxation del Monte et al., 2002
PHOSPHO 
LAMBAN
myocardial 
cells 
Silencing of 
PLB sheep
velocities. 
Improved SERCA activity, improved systolic 
and diastolic LV function.
Kaye et al., 2007 
Mice Enhanced Ca2+ kinetics. Kiriazis et al., 2000
PARV
ALBUMIN
Dog cardio 
myocytes
Improved relaxation kinetics but depressed 
sarcomere shortening at higher parvalbumin 
concentrations. 
Hirsch et al., 2004 
Cardiomyoc 
ytes 
Increase of isometric contraction followed by 
an increase in the amount of Ca2+ pumped 
into the SR. 
Mice 
Substantially worsened LV function, 
transaortic constriction and MI with 
Remppis et al., 1996
Intracoronar 
significantly lower survival. Most et al., 2006 
S100A1
y delivery 
of AAV6­
S100A1Post­
MI rat heart 
AdV-
LV dysfunction and HF was evident initially 
and 2 months after gene delivery, S100A1­
treated HF rats presented with significantly 
enhanced cardiac function and a reversal of
LV remodeling compared to control HF rats. 
Pleger et al., 2007 
mediated
S100A1 gene
transfer to
failing rat
cardiomyocy 
Restoration of disturbed 
Ca2+ handling by increasing reuptake of SR 
Ca2+ during the relaxation phase and a 
lowering of the RyR-mediated Ca2+ leak. 
Most et al., 2004 
tes 
Table 4. The examples of various proteins involved in calcium signaling studied for gene 
therapy. 
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277Preclinical and Clinical Prospects of Gene Therapy in Myocardial Infarction 
2.5 Role of cell cycle activation in gene therapy 
The normal cell passes through the stages of G1-S-G2-M in that orderly sequence as a part of 
the cell cycle; with a quiescent G0 phase before entering the S phase from G1. This cell cycle 
is highly subject to strict regulation by a number of molecules that either enhance or retard
the progression of the cycle. The two important check-points G1-S and G2-M demand the 
requirement of a group of proteins called cyclins to overcome them; that do so by combining 
with a group of cyclin-dependent kinases (CDKs). The expression of cyclins is enhanced by 
dephosphorylation of Rb protein; mutations in which are found to be responsible for the 
ocular tumour retinoblastoma. Similarly, the CDKs are inhibited by the proteins of the
Cip/Kip family as well as those of the p16/INK4a locus. A major role is also played by p53 
protein, that halts the cell cycle, allowing time for the DNA damage to be rectified; if
successful, terminates its own action by inducing autocatalysis through induction of MdM2 
and if the DNA damage cannot be repaired, initiates apoptosis. Cell cycle activation is 
another promising application of gene therapy which results in the induction of endogenous
myocardial regeneration. In various pre-clinical set ups it has resulted in activation of the 
cardiomyocyte cell cycle, thereby limiting the infarct size and improving LV dysfunction.
The cyclins and the CDKs are the various candidate genes, the induction of which permits 
the cell to overcome the endogenous checkpoints and continue with the replication, thus
allowing the cardiomyocyte growth. Studies in animals have yielded encouraging results, as 
listed in the following table; while clinical trials in humans are still awaited (Table 5). 
Target 
Gene 
Species Outcome Reference 
Cyclin -A2 Rats 
Increased border-zone myofilament 
density and improved myocardial
function 
Woo et al., 2006 
CDK4 Rats Improved left ventricular function
Tamamori-Adachi
et al., 2008
Table 5. The examples of proteins involved in cell cycle studied for gene therapy.
2.6 Role of β-adrenergic system in gene therapy 
ǃ-adrenergic receptor blockers have been shown to exert favorable effects in heart-failure
patients. Numerous clinical and experimental studies have shown that molecular targeting 
of various proteins within the cardiac beta-adrenergic receptor (ǃ-ARs) pathway may be
beneficial in heart failure. Chronic heart failure due to MI is associated with increased  
sympathetic discharge. However, this increased sympathetic activity is compensated
mechanistically, but is more injurious in the long term. The ǃ-adrenergic system is affected 
by multiple modifications including ǃ-AR down-regulation, up-regulation of ǃ-AR kinases 
and increased Gi function leading to ǃ-AR desensitization and decreased ǃ-AR signaling 
activity in heart failure. Several gene-based experiments tested and established that cardiac 
functions are improved or enhanced by genetic manipulation of the myocardial ǃ-AR
system.
2.6.1 β2-adrenergic receptor overexpression 
Although ǃ2-AR overexpression in mouse hearts results in improved systolic and diastolic
function; but at significantly high levels, mice developed fibrotic cardiomyopathy and heart 
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failure. Moreover, ǃ2 signaling stimulates cell-survival and protects myocyte damage from
apoptosis. This fact led to the use of ǃ2-AR gene delivery in various experimental models of 
heart failure (Table 6). 
2.6.2 Inhibition of G protein-coupled receptor kinases (GRKs)
Homologous desensitization (agonist dependent) is mediated by G protein–coupled
receptor kinases (GRKs). GRK-2 upregulation is responsible for ǃ-AR desensitization in 
heart failure and these kinases dampen the interaction between ǃ-receptors and their G 
proteins. In addition, ǃ-ARKct is a peptide within the carboxy terminus of GRK2 that
inhibits GRK-2 mediated ǃ-AR desensitization. ǃARKct gene transfer to isolated failing
human cardiomyocytes improved their contractile function. 
2.6.3 Adenylatecyclase type 6 
ǃ-AR stimulation activates adenylate cyclase (AC) through G-protein activation and AC 
then activates protein kinases to exert its downstream effects. AC6 is the predominant
cardiac isoform and its overexpression in cardiac tissue leads to increased left ventricle 
contractility and function.
Target 
Gene 
Species Outcome References 
ǃ-ARs AdVǃ-AR 
intracorona 
ry delivery
mice
Enhanced cardiac function. Shah et al., 2000 
Inhibition 
of GRK­
2by 
ǃARKct 
gene 
transfer 
Isolated 
failing
human 
cardiomyo 
cytes
Intracorona 
ry delivery
of AdV­
ǃARKct in
mice
Improved their contractile function. 
Improved cardiac function post-MI.
Jameel & Zhang, 
2009 
Iaccarino et al.,
1998 
Adenylate 
cyclase
type 6 
AdV-AC6 
gene 
delivery in 
pigs
Improved LV contractility and function. Lai et al., 2004
Table 6. Proteins involved in ǃ-adrenergic system studied for gene therapy. 
3. Clinical aspects
The human quest and efforts to expand the boundaries of his knowledge into the arena of 
gene therapy is endless. Genes responsible for cardiovascular events or diseases, myocardial 
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Clinical Trial
Sample 
size = 
n 
Outcome References 
Intramyocardial 
injection of adenovirus
(Ad.VEGF-121) by 
thoracotomy & CABG /
by minimally invasive 
thoracotomy 
21 
Both groups showed reduction in 
angina but no improvement in 
exercise duration. 
Proper conclusions could not be 
drawn due to absence of control 
group.
Rosengart et 
al., 1999
Injection of ph.VEGF­
165 into LV 
myocardium by 
minimally invasive
thoracotomy 
5 
20 
Reduction in angina and 
nitroglycerine use in 60 days in all 5
patients. 
Results limited because of a small 
sample size and absence of controls. 
Reduction in angina and 
nitroglycerine use in 90 days in 16 
out of 20 patients. 
Results limited due to absence of 
controls.
Losordo et
al., 1998
Administration of 
VEGF-165
20 
Significant symptomatic
improvement in patients with 
inoperable CAD 
Symes et al.,
1999 
Catheter-mediated 
VEGF 
plasmid/liposome 
(P/L) gene transfer 
15 
Catheter-mediated intracoronary 
gene transfer performed after 
angioplasty significantly prevents 
restenosis and myocardial ischemia. 
Laitinen et
al., 2000
Percutaneous catheter-
based gene transfer of 
naked plasmid DNA for 
VEGF-2 to LV 
myocardium
19 
Decrease in angina & improvement 
in symptoms. 
Drawback: sample size is low. 
Losordo et
al., 2002
Table 7. Clinical trials for gene therapy in myocardial infarction. Ad.VEGF-121: Adenovirus 
encoding Vascular Endothelial Growth Factor-121; ph.VEGF-165: Plasmid vector encoding
Vascular Endothelial Growth Factor-165; Ad.FGF-4: Adenovirus encoding Fibroblast 
Growth Factor-4; LV: Left ventricle; LacZ: Z gene of lac operon; HIF-ǂ: Hypoxia-Inducible 
Factor-ǂ. 
infarction in particular, have been identified and targeted as a means of curative approach. 
An example can be illustrated of the study conducted by Doney and his colleagues (Doney
et al., 2009) who identified an allele of rs9939609 gene, also referred to as FTO (Fat mass and
obesity associated) gene. This gene increased the risk of Type II diabetes mellitus, an 
atherogenic lipid profile (including decreased high density lipoprotein and increased 
triglycerides) and myocardial infarction. This allele presents a target which if suitably
replaced by the wild type can decrease the risks for all the above conditions.
One of the main drawbacks for designing gene therapy for myocardial infarction is the
ethical concerns pertaining to the selection of participants. The participants are among those
who have suffered an attack of myocardial infarction and conducting studies on such a 
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cohort of patients with a risk of failure of  therapy raises a substantial debate. Apart from
this, the set-up for these studies also demands technical and financial support on a 
tremendously large scale. It is for these very precise reasons that a large number of these
studies have not yet been conducted so far and hence the relative paucity of these studies in 
literature as compared to other studies. However the recent advances in the study of human 
genome and identification of genes associated with the risk factors, pathogenesis as well as 
outcome of myocardial infarction, has given a great impetus for designing clinical trials for 
gene therapy. As a result, a good number of trials are currently underway, for instance, the
endocardial gene therapy with VEGF-D for severe coronary heart disease. 
Apart from the ethical and financial constraints, there are practical difficulties as well, for 
instance, the delivery of viral particles in to the human body may stimulate the immune
system that stimulates the T lymphocytes and cytokines to clear the virus. The naked DNA 
administered may be lysed by DNAses present in the serum. The permeability of the naked
DNA across cell membranes is also restricted, necessitating the requirement for intracellular 
transfer. On the other hand, an intravenous injection may result in transfection of other 
tissues apart from the heart and lodgement of the vectors in other organs such as the lung or 
kidney. To circumvent these possibilities, the technology required for gene transfer needs to
be highly advanced and sophisticated to ensure that the vector containing the therapeutic 
gene transfects only the desired myocardial cells. An example of such technology is the 
UTMD (ultrasound targeted microbubble destruction), in which ultrasound contrast agents 
used as gas microbubbles, are packed with the therapeutic gene containing DNA and are 
destroyed within the myocardium by subjecting them to high ultrasound frequency. A very
high number of clinical trials have not been conducted for gene therapy in MI. Some of the
clinical trials that have been undertaken in this regard are enlisted in table 7. 
4. Limitations of gene therapy
As with most experimental therapies, safety of gene therapy for ischemic heart disease is of
paramount importance. Though clinical trials have shown short-term safety, long-term 
surveillance over a period of decades is lacking. The question still remains as to which 
therapy benefits what sub-population of patients. Inclusion of a wide selection of patients in 
studies over time may lead to improvement in subgroups of patients if not the entire
population. Confounding factors such as use of concurrent medications and concurrent 
medical conditions lead to difficulty in standardizing groups of patients. Objective end 
points of assessment need to be used uniformly as exercise testing may be subjective and is
victim to high variability in the same patient on different days. Frequency of testing for 
objective improvements may need to be ramped up as the effects of therapeutic genes may 
have abated at the time of a single test. Another surprising factor that confounded results of 
clinical trials was a strong placebo effect. This might be minimized when objective and not
subjective end points are used when assessing outcomes. Drug related issues such as the 
dose, gene transfection efficiency, pharmacokinetics and pharmacodynamics of individual 
therapies are valid as these may differ in different populations of patients. Also cost-
effectiveness analysis has to be considered, as production of gene therapy vectors itself is
cumbersome, requires specialized equipment and personnel and the administration of gene
therapy is invasive in nature. Besides, specific gene therapy may not compare favourably to 
available pharmacological agents in use to treat ischemic heart disease in terms of cost-
benefit ratio.
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5. Conclusions and future directions
As of now, the applications of gene therapy for treatment of human diseases, including 
cardiovascular conditions, though appears to be extremely promising and fascinating, is, in 
the true sense of the term, still in its infancy. A vast magnitude of studies, not only on
humans, but further studies on animal models, are still necessary to validate the practical 
efficacy of this widely-sought-after approach. Overcoming the practical difficulties 
discussed above is not an easy task and a tremendous amount of finance and infrastructure
is an inevitable requirement to achieve this goal. In spite of that, there still remains a 
possibility that the gene therapeutically administered may not be expressed in the target
individual, subject to an inability of the vectors to reach the target tissue, metabolism of the
vectors by the immune system or the presence of other intracellular substances that may
exert a negative regulation on the gene expression. 
It is possible that extensive use of small animals for pre-clinical research may have led to 
excessive enthusiasm too early. Gene therapy testing on larger animals may provide a better
insight into the true efficacy of specific therapies.
However, these shortcomings should not prove to be a permanent obstacle as the prospects 
offered by the advent of gene therapy have been extremely fascinating. The elucidation of
the human genome has exposed a vast array of genes that are responsible for umpteen 
number of diseases; such as cystic fibrosis, familial hypercholesterolemia, Lesch-Nyhan 
syndrome, Alzheimer’s disease, Parkinson’s disease, Duchenne muscular dystrophy,
multiple sclerosis and others. These genes offer potential candidates for regulation that can 
alter the course of the disease as against the current medications available that mainly
provide symptomatic relief. Thus, the future for gene therapy appears to be very bright. A
good political establishment to provide the necessary infrastructure and monetary support 
might go a long way to circumvent the existing shortcomings and empower gene therapy to 
grow as the most preferred and successful therapeutic approach to most of the diseases that 
were considered incurable till the past few decades.
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